Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its phase-1 metabolites in human biological fluids.
Journal of pharmaceutical and biomedical analysis January 20, 2024 Alfredo Fabrizio Lo Faro, Giorgia Sprega, Diletta Beradinelli et al. 14 citations
Enantioselective high-performance liquid chromatography-tandem mass spectrometry methods were developed to quantify MDMA and its phase-1 metabolites HMA, HMMA, and MDA in human plasma, sweat, oral fluid, and urine. Two polysaccharide-based chiral columns achieved baseline separation of most enantiomer pairs: the Lux AMP column separated MDMA, HMA, and HMMA enantiomers but not MDA; the Lux i-Amylose-3 column separated MDMA, HMMA, and MDA enantiomers but not HMA. Analysis took under 4 minutes with one column and under 6 minutes with the other. Both methods were validated and applied to biological fluids, confirming enantioselective metabolism of MDMA.